A Real-world Comparison of Circulating Tumor Cells in Breast Cancer from China: Novel Device, CTC Counts and Its Overall Survival

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Apr 16

PMID 38623216

Authors

Feng Li

Jianbin Li

Yang Yuan

Huiqiang Zhang

Shaohua Zhang

Li Bian

Tao Wang

Zefei Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Both CellSearch and CellCollector have been accepted as the proper devices to capture CTC by domestic approval department. However, there is little article about the comparison between these two devices around the world. Herein, we conducted the real-world study to compare with these two devices and to re-verify the efficacy of CTC counts.

Methods: Patients who meet the following points should be included in the analysis. 1. Female, aged 18 years or older; 2. Eastern Cooperative Oncology Group (ECOG) score 0-2; 3. With at least one measurable tumor lesion; 4. Clear immunohistochemistry result; 5. Accept at least one CTC test. Patients were excluded in the analysis if they had a history of malignant tumors, incomplete follow-up information.

Results: 536 metastatic breast cancer patients who had been detected for CTC at least once by CellSearch or CellCollector were included in the analysis. CellCollector CTC detection technology has a higher detection rate than the CellSearch system (69.2% vs 57.4%, P = 0.009). However, the proportion of CTC≥5 detected by CellSearch was higher than CellCollector (37.4% vs 16.3%, P < 0.001). There was a statistically significant difference in overall survival of patients with CTC negative and CTC positive (mOS:49.8 months vs 26.9 months). After 4 weeks of treatment, when CTC decreased by more than 50%, there was a significant difference in survival between the two groups (40.1 months vs 25.8 months, HR = 0.588, 95% CI: 0.350-0.933). In addition, for HER2-positive patients, Patients with CTC HER2 positive had longer overall survival than patients with CTC HER2 negative (median OS: 26.7 months vs 17.3 month, HR = 0.528, 95% CI: 0.269-0.887).

Conclusions: Real-world data indicate that CTC is an independent prognostic factor, and CellCollector and CellSearch have their own advantages in CTC detection.

References

Li J, Geng C, Yan M, Wang Y, Ouyang Q, Yin Y . [Circulating tumor cells in patients with breast tumors were detected by a novel device: a multicenter, clinical trial in China]. Zhonghua Yi Xue Za Zhi. 2017; 97(24):1857-1861. DOI: 10.3760/cma.j.issn.0376-2491.2017.24.003. View

Heller G, McCormack R, Kheoh T, Molina A, Smith M, Dreicer R . Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol. 2017; 36(6):572-580. PMC: 5815402. DOI: 10.1200/JCO.2017.75.2998. View

Riethdorf S, Muller V, Loibl S, Nekljudova V, Weber K, Huober J . Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clin Cancer Res. 2017; 23(18):5384-5393. DOI: 10.1158/1078-0432.CCR-17-0255. View

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R . Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer. 2008; 113(9):2422-30. DOI: 10.1002/cncr.23852. View

Li S, Yang S, Shi J, Ding Y, Gao W, Cheng M . Recognition of the organ-specific mutations in metastatic breast cancer by circulating tumor cells isolated in vivo. Neoplasma. 2020; 68(1):31-39. DOI: 10.4149/neo_2020_200317N275. View

Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P . A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol. 2012; 41(4):1241-50. PMC: 3583719. DOI: 10.3892/ijo.2012.1557. View

Jiang Z, Cristofanilli M, Shao Z, Tong Z, Song E, Wang X . Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol. 2013; 24(11):2766-72. DOI: 10.1093/annonc/mdt246. View

Lawrence R, Watters M, Davies C, Pantel K, Lu Y . Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023; 20(7):487-500. PMC: 10237083. DOI: 10.1038/s41571-023-00781-y. View

Smerage J, Barlow W, Hortobagyi G, Winer E, Leyland-Jones B, Srkalovic G . Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014; 32(31):3483-9. PMC: 4209100. DOI: 10.1200/JCO.2014.56.2561. View

10.

Duan G, Zhang X, Wang H, Wang Z, Zhang H, Yu L . Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer. Onco Targets Ther. 2020; 13:1931-1939. PMC: 7061431. DOI: 10.2147/OTT.S241956. View

11.

Chakraborty R, Lentzsch S . Circulating Tumor Cell Burden as a Component of Staging in Multiple Myeloma: Ready for Prime Time?. J Clin Oncol. 2022; 40(27):3099-3102. DOI: 10.1200/JCO.22.01040. View

12.

He Y, Shi J, Schmidt B, Liu Q, Shi G, Xu X . Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer. Cancer Manag Res. 2020; 12:841-854. PMC: 7008188. DOI: 10.2147/CMAR.S240773. View

13.

Vermesh O, Aalipour A, Ge T, Saenz Y, Guo Y, Alam I . An intravascular magnetic wire for the high-throughput retrieval of circulating tumour cells in vivo. Nat Biomed Eng. 2018; 2(9):696-705. PMC: 6261517. DOI: 10.1038/s41551-018-0257-3. View

14.

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

15.

Goei A, Kurth T . Considerations for Use of Propensity Score Matching in Specific Patient Populations. JAMA Surg. 2022; 157(8):743-744. DOI: 10.1001/jamasurg.2022.1495. View

16.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S . Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol. 2009; 27(13):2177-84. DOI: 10.1200/JCO.2008.18.0497. View

17.

Guo S, Huang J, Li G, Chen W, Li Z, Lei J . The role of extracellular vesicles in circulating tumor cell-mediated distant metastasis. Mol Cancer. 2023; 22(1):193. PMC: 10688140. DOI: 10.1186/s12943-023-01909-5. View

18.

Boya M, Ozkaya-Ahmadov T, Swain B, Chu C, Asmare N, Civelekoglu O . High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells. Nat Commun. 2022; 13(1):3385. PMC: 9192591. DOI: 10.1038/s41467-022-31009-9. View

19.

Zheng S, Girgis M, Tomlinson J . Circulating Tumor Cells: Metastases Caught in the Act. Ann Surg. 2023; 277(6):873-876. DOI: 10.1097/SLA.0000000000005846. View

20.

Xie W, Suryaprakash S, Wu C, Rodriguez A, Fraterman S . Trends in the use of liquid biopsy in oncology. Nat Rev Drug Discov. 2023; 22(8):612-613. DOI: 10.1038/d41573-023-00111-y. View